Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "HER2-positive breast cancer treatment"

Henlius and Organon Win EC Nod for POHERDY, Biosimilar to PERJETA

European Commission (EC) approves Shanghai Henlius Biotech Inc. and Organon & Co.’s POHERDY (pertuzumab), the first PERJETA biosimilar in Europe, backed by strong analytical, clinical, safety, and immunogenicity data.

HER2-positive Breast Cancer Treatment | 30/04/2026 | By News Bureau

DualityBio Secures China NMPA BLA Acceptance for Trastuzumab Pamirtecan in HER2+ Breast Cancer

DualityBio announces China NMPA acceptance of its BLA for trastuzumab pamirtecan, targeting unresectable or metastatic HER2-positive breast cancer in adult patients.

HER2-positive Breast Cancer Treatment | 10/04/2026 | By News Bureau

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members